FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224315707> ?p ?o ?g. }

• W4224315707 abstract "Abstract Background/Aims Coronavirus Disease 2019 (COVID-19) is a global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). International mass vaccination schemes are implemented to control the disease and reduce mortality. The data on serological immune response among rheumatology patients receiving immunosuppressive therapy following SARS-CoV-2 vaccines is very sparse. We present a case of a rheumatoid arthritis patient receiving rituximab (RTX) who developed fatal nosocomial COVID-19 infection despite receiving SARS-CoV-2 vaccine. Methods A 71-year-old Caucasian male with longstanding seropositive rheumatoid arthritis, interstitial lung disease with bullous emphysema, paraproteinemia, osteoporosis, anxiety, and depression. His treatment included hydroxychloroquine, sulfasalazine, oral prednisolone (2-5 mg), and RTX every 6 months. He received his last cycle of RTX almost 8 weeks before vaccination. This gentleman received two doses of COVID-19 mRNA Vaccine (BioNTech-Pfizer) eleven weeks apart. Nine weeks after the second vaccination he was admitted with supraventricular tachycardia and heart failure. This admission coincided with a COVID-19 outbreak in the ward. Eight patients and one staff member tested (PCR) positive during regular ward screening. All patients were initially asymptomatic, and six of them were fully vaccinated. He was allowed to go home with advice to self-isolate for 10 days. Two days after discharge, he presented to the emergency department with shortness of breath, lethargy, and cough. The diagnosis was COVID-19 pneumonitis and pre-renal acute kidney injury. He received supplemental oxygen, dexamethasone, and intravenous co-amoxiclav. Unfortunately, he died from COVID-19 pneumonitis on his sixth day of admission. Our patient was the only one among the nine SARS-CoV-2 positive individuals who developed symptomatic disease. Results It is known that RTX along with other immune modulatory drugs reduce the response to some vaccines such as the seasonal flu vaccine, and it is expected that the same effect could be seen after COVID-19 vaccination. Octave study is evaluating immune responses in patients with a range of chronic rheumatic conditions on specific immunomodulatory and biologic treatments. This has shown the response to vaccine was dependent on the disease cohort, with 90% of those with RTX-treated antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and 54% of those with inflammatory arthritis responding less well than the baseline for healthy subjects. There is no evidence to suggest how long after RTX a patient should delay vaccination with a COVID-19 vaccine, but published consensus suggests 4-8 weeks. Conclusion More studies are needed to assess the response to SARS-COV-2 vaccines among immunocompromised patients and the need for a third vaccine dose if antibodies level were low. The first approved monoclonal antibody treatment—Ronapreve™ for treating and preventing acute covid-19 in adults, is a promising drug for poor vaccine responders who develop COVID-19 infection. This case also highlights the importance of infection control within hospital setting. Disclosure N. Abdullah: None. A. Kinder: None. D. Jenkins: None. V. Patel: None." @default.
• W4224315707 created "2022-04-26" @default.
• W4224315707 creator A5013657127 @default.
• W4224315707 creator A5015921728 @default.
• W4224315707 creator A5021833949 @default.
• W4224315707 creator A5068531142 @default.
• W4224315707 date "2022-04-23" @default.
• W4224315707 modified "2023-10-17" @default.
• W4224315707 title "P073 Patient with rheumatoid arthritis on regular rituximab infusions with severe COVID-19 pneumonitis despite both vaccinations" @default.
• W4224315707 doi "https://doi.org/10.1093/rheumatology/keac133.072" @default.
• W4224315707 hasPublicationYear "2022" @default.
• W4224315707 type Work @default.
• W4224315707 citedByCount "1" @default.
• W4224315707 countsByYear W42243157072022 @default.
• W4224315707 crossrefType "journal-article" @default.
• W4224315707 hasAuthorship W4224315707A5013657127 @default.
• W4224315707 hasAuthorship W4224315707A5015921728 @default.
• W4224315707 hasAuthorship W4224315707A5021833949 @default.
• W4224315707 hasAuthorship W4224315707A5068531142 @default.
• W4224315707 hasBestOaLocation W42243157071 @default.
• W4224315707 hasConcept C126322002 @default.
• W4224315707 hasConcept C141071460 @default.
• W4224315707 hasConcept C198451711 @default.
• W4224315707 hasConcept C203014093 @default.
• W4224315707 hasConcept C22070199 @default.
• W4224315707 hasConcept C2776715498 @default.
• W4224315707 hasConcept C2777178219 @default.
• W4224315707 hasConcept C2777575956 @default.
• W4224315707 hasConcept C2777910003 @default.
• W4224315707 hasConcept C2777914695 @default.
• W4224315707 hasConcept C2779123688 @default.
• W4224315707 hasConcept C2779134260 @default.
• W4224315707 hasConcept C2779338263 @default.
• W4224315707 hasConcept C2780653079 @default.
• W4224315707 hasConcept C3008058167 @default.
• W4224315707 hasConcept C524204448 @default.
• W4224315707 hasConcept C71924100 @default.
• W4224315707 hasConceptScore W4224315707C126322002 @default.
• W4224315707 hasConceptScore W4224315707C141071460 @default.
• W4224315707 hasConceptScore W4224315707C198451711 @default.
• W4224315707 hasConceptScore W4224315707C203014093 @default.
• W4224315707 hasConceptScore W4224315707C22070199 @default.
• W4224315707 hasConceptScore W4224315707C2776715498 @default.
• W4224315707 hasConceptScore W4224315707C2777178219 @default.
• W4224315707 hasConceptScore W4224315707C2777575956 @default.
• W4224315707 hasConceptScore W4224315707C2777910003 @default.
• W4224315707 hasConceptScore W4224315707C2777914695 @default.
• W4224315707 hasConceptScore W4224315707C2779123688 @default.
• W4224315707 hasConceptScore W4224315707C2779134260 @default.
• W4224315707 hasConceptScore W4224315707C2779338263 @default.
• W4224315707 hasConceptScore W4224315707C2780653079 @default.
• W4224315707 hasConceptScore W4224315707C3008058167 @default.
• W4224315707 hasConceptScore W4224315707C524204448 @default.
• W4224315707 hasConceptScore W4224315707C71924100 @default.
• W4224315707 hasIssue "Supplement_1" @default.
• W4224315707 hasLocation W42243157071 @default.
• W4224315707 hasLocation W42243157072 @default.
• W4224315707 hasOpenAccess W4224315707 @default.
• W4224315707 hasPrimaryLocation W42243157071 @default.
• W4224315707 hasRelatedWork W2101533154 @default.
• W4224315707 hasRelatedWork W2119875305 @default.
• W4224315707 hasRelatedWork W2126275861 @default.
• W4224315707 hasRelatedWork W2313613548 @default.
• W4224315707 hasRelatedWork W2409636163 @default.
• W4224315707 hasRelatedWork W2558297493 @default.
• W4224315707 hasRelatedWork W2936228890 @default.
• W4224315707 hasRelatedWork W2940996734 @default.
• W4224315707 hasRelatedWork W3154539840 @default.
• W4224315707 hasRelatedWork W3205112640 @default.
• W4224315707 hasVolume "61" @default.
• W4224315707 isParatext "false" @default.
• W4224315707 isRetracted "false" @default.
• W4224315707 workType "article" @default.